DB
IRWD icon

Dmitry Balyasny’s Ironwood Pharmaceuticals IRWD Stock Holding History

Dmitry Balyasny’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$436K – 2830
2024
Q1 		$436K Sell
50,000
-325,000
-87% -$3.94M ﹤0.01% 2104
2023
Q4 		$4.29M Buy
+375,000
New +$3.71M 0.01% 1169

Other funds holding IRWD

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's IRWD Position: Q1 2026 in Review

Dmitry Balyasny sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 65,156 shares — an estimated $220K sold.

Dmitry Balyasny first reported a position in IRWD in Q1 2018 and held it in 15 quarters. The position peaked at $18M in Q2 2023. 227 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Dmitry Balyasny reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 65,156 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $220K.
  • Dmitry Balyasny first reported a position in Ironwood Pharmaceuticals in Q1 2018 and held it in 15 quarters.
  • Dmitry Balyasny's Ironwood Pharmaceuticals position peaked at $18M in Q2 2023.
  • 227 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.